Literature DB >> 28050648

Diagnostic value of antibodies to phosphatidylserine/prothrombin complex for antiphospholipid syndrome in Chinese patients.

Lei Zhu1,2,3, Chun Li1,2,3, Na Liu1,2,3, Xin Yang1,2,3, R L Jia1,2,3, Rong Mu4,5,6, Yin Su1,2,3, Z G Li1,2,3.   

Abstract

To evaluate the diagnosis value of antibodies to phosphatidylserine/prothrombin complex (aPS/PT) in patients with antiphospholipid syndrome (APS) and to determine the clinical features of APS patients with avidity of aPS/PT. Serum samples were collected from 108 APS patients. Sixty patients with pregnancy morbidity, 37 patients with thrombosis without a history of autoimmune diseases, and 89 healthy blood donors were included as the control group. The enzyme-linked immunosorbent assay (ELISA) test was performed to detect the concentration of aPS/PT, including IgG/M, IgG, and IgM forms, in the same serum sample. The chi-square (χ2) test was used to examine the difference of frequencies of antibodies in APS patients and patients with other diseases. Spearman correlation analysis was performed to investigate the relationship between aPS/PT and other clinical/laboratory parameters. aPS/PT was detectable in 68 (63.0%) of the 108 APS patients, 12 (13.2%) of the 91 disease control patients and 1 (1.1%) of the healthy controls. It was strongly correlated with the activity of lupus anticoagulant (LA) (OR 15.952, 95% CI 7.132-35.678; P < 0.001). The frequency of aPS/PT was 56.9% in anti-cardiolipid antibody (aCL)-negative, 60.5% anti-β2 glycoprotein I antibody (aβ2GPI)-negative, and 50.0% in both aCL and aβ2GPI negative APS patients. The IgG aPS/PT was significantly associated with arterial and venous thrombosis. The aPS/PT antibody could play an important role in the diagnosis of APS, especially in patients with negative aCL and aβ2GPI. It was positively related to thrombotic events in APS.

Entities:  

Keywords:  Antiphosphatidylserine/prothrombin antibodies; Antiphospholipid; Pregnancy morbidity; Sensitivity; Specificity; Syndrome·thrombosis

Mesh:

Substances:

Year:  2017        PMID: 28050648     DOI: 10.1007/s10067-016-3498-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  28 in total

Review 1.  Update on antiphospholipid antibodies.

Authors:  R A Roubey
Journal:  Curr Opin Rheumatol       Date:  2000-09       Impact factor: 5.006

2.  Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called 'seronegative APS').

Authors:  Jose Luis Rodriguez-Garcia; Maria Laura Bertolaccini; Maria Jose Cuadrado; Giovanni Sanna; Oier Ateka-Barrutia; Munther A Khamashta
Journal:  Ann Rheum Dis       Date:  2011-09-27       Impact factor: 19.103

3.  Occurrence of anti-prothrombin and anti-beta2-glycoprotein I antibodies in patients with history of thrombosis.

Authors:  R Forastiero; M Martinuzzo; Y Adamczuk; L O Carreras
Journal:  J Lab Clin Med       Date:  1999-12

4.  Antiprothrombin antibody: why do we need more assays?

Authors:  T Atsumi; T Koike
Journal:  Lupus       Date:  2010-04       Impact factor: 2.911

Review 5.  Antiprothrombin antibody testing: detection and clinical utility.

Authors:  Kenji Oku; Tatsuya Atsumi; Olga Amengual; Takao Koike
Journal:  Semin Thromb Hemost       Date:  2008-09-23       Impact factor: 4.180

6.  Lupus anticoagulant diagnosis in activated partial thromboplastin time mixing test: optimization of the index of circulating anticoagulant cut-off value.

Authors:  Osamu Kumano; Masahiro Ieko; Sumiyoshi Naito; Mika Yoshida; Nobuhiko Takahashi; Takeshi Suzuki; Takashi Aoki
Journal:  Clin Lab       Date:  2014       Impact factor: 1.138

7.  Anti-prothrombin antibodies and the lupus anticoagulant.

Authors:  R A Fleck; S I Rapaport; L V Rao
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

Review 8.  Antiphospholipid antibody testing and standardization.

Authors:  K M J Devreese
Journal:  Int J Lab Hematol       Date:  2014-06       Impact factor: 2.877

9.  Antiphosphatidylserine/prothrombin antibodies in primary antiphospholipid syndrome.

Authors:  A Hoxha; A Ruffatti; M Tonello; A Bontadi; E Salvan; A Banzato; V Pengo; L Punzi
Journal:  Lupus       Date:  2012-06       Impact factor: 2.911

10.  The introduction of anti-phosphatidylserine/prothrombin autoantibodies in the laboratory diagnostic process of anti-phospholipid antibody syndrome: 6 months of observation.

Authors:  Martina Fabris; Roberta Giacomello; Alessandra Poz; Lisa Pantarotto; Nicolanna Tanzi; Francesco Curcio; Elio Tonutti
Journal:  Auto Immun Highlights       Date:  2014-08-14
View more
  3 in total

1.  Characteristics of pregnancy complications and treatment in obstetric antiphospholipid syndrome in China.

Authors:  Zhuochao Zhou; Jialin Teng; Yue Sun; Honglei Liu; Xiaobing Cheng; Yutong Su; Chengde Yang; Junna Ye
Journal:  Clin Rheumatol       Date:  2019-07-09       Impact factor: 2.980

2.  Antiphospholipid antibody syndrome with thrombotic splenic infarcts associated with acute cytomegalovirus infection.

Authors:  Christopher Denham; Ginger Tissier; Amit Golding
Journal:  Access Microbiol       Date:  2019-06-10

3.  Evaluation of the Diagnostic Value of Non-criteria Antibodies for Antiphospholipid Syndrome Patients in a Chinese Cohort.

Authors:  Chaojun Hu; Siting Li; Zhijuan Xie; Hanxiao You; Hui Jiang; Yu Shi; Wanting Qi; Jiuliang Zhao; Qian Wang; Xinping Tian; Mengtao Li; Yan Zhao; Xiaofeng Zeng
Journal:  Front Immunol       Date:  2021-09-10       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.